Celyad Oncology S.A.
CLYYF - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$14.24M
Close$
$0.04
86.2% downside
Current Fair Value
86.2% downsideOvervalued by 86.2% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $14.24 Million |
|---|---|
| Enterprise Value | $14.51 Million |
| Earnings per Share | $0.02 |
| Beta | 1.21 |
| Outstanding Shares | 44,761,905 |
Return
| Return on Equity | -253.58% |
|---|---|
| Return on Assets | -136.99% |
| Return on Invested Capital | -809.82% |
Valuation & Multiples
| P/E Ratio | 2.7 |
|---|---|
| PEG | -4.01 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 75.18 |
| Enterprise Value to EBIT | -1.28 |
| Enterprise Value to Net Income | -5 |
| Total Debt to Enterprise | 0.03 |
| Debt to Equity | 0.31 |
Revenue Sources
No data
Last Earnings Call
Report Date
September 23, 2026
EPS Estimate
-
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateNext Earnings Call
Expected Date
March 25, 2027
EPS Estimate
-
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About Celyad Oncology
17 employees
CEO: Filippo Petti
Celyad Oncology SA is a clinical-stage biopharmaceutical entity dedicated to the discovery and advancement of chimeric antigen receptor T (CAR-T) cell therapies for cancer treatment. Its prominent clinical programs include CYAD-101, an a...